Next Article in Journal
Nuclear Export Inhibition for Pancreatic Cancer Therapy
Next Article in Special Issue
Toward the Discovery of a Novel Class of YAP–TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP–TEAD Protein–Protein Interface
Previous Article in Journal
Electron Nuclear Dynamics Simulations of Proton Cancer Therapy Reactions: Water Radiolysis and Proton- and Electron-Induced DNA Damage in Computational Prototypes
Previous Article in Special Issue
The Hippo-YAP Pathway Regulates 3D Organ Formation and Homeostasis
Review

YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting

1
Oncogenomic and Epigenetic Unit, Molecular Medicine Area Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome, Italy
2
Molecular Chemoprevention Group, Molecular Medicine Area Regina Elena National Cancer Institute, via Elio Chianesi 53 00144 Rome, Italy
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(5), 137; https://doi.org/10.3390/cancers10050137
Received: 30 March 2018 / Revised: 1 May 2018 / Accepted: 2 May 2018 / Published: 6 May 2018
Lung cancer is the leading cause of cancer death in the world and there is no current treatment able to efficiently treat the disease as the tumor is often diagnosed at an advanced stage. Moreover, cancer cells are often resistant or acquire resistance to the treatment. Further knowledge of the mechanisms driving lung tumorigenesis, aggressiveness, metastasization, and resistance to treatments could provide new tools for detecting the disease at an earlier stage and for a better response to therapy. In this scenario, Yes Associated Protein (YAP) and Trascriptional Coactivator with PDZ-binding motif (TAZ), the final effectors of the Hippo signaling transduction pathway, are emerging as promising therapeutic targets. Here, we will discuss the most recent advances made in YAP and TAZ biology in lung cancer and, more importantly, on the newly discovered mechanisms of YAP and TAZ inhibition in lung cancer as well as their clinical implications.
View Full-Text
Keywords: YAP/TAZ; lung cancer; NSCLC; therapeutic targets YAP/TAZ; lung cancer; NSCLC; therapeutic targets
Show Figures

Figure 1

MDPI and ACS Style

Lo Sardo, F.; Strano, S.; Blandino, G. YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Cancers 2018, 10, 137. https://doi.org/10.3390/cancers10050137

AMA Style

Lo Sardo F, Strano S, Blandino G. YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Cancers. 2018; 10(5):137. https://doi.org/10.3390/cancers10050137

Chicago/Turabian Style

Lo Sardo, Federica, Sabrina Strano, and Giovanni Blandino. 2018. "YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting" Cancers 10, no. 5: 137. https://doi.org/10.3390/cancers10050137

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop